Helen Winter

Helen Winter

Auto-generated profile, based on publicly available information

Helen Winter

Gilead Sciences, Inc. Foster City California USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2012 in The Clinical Teacher
Verified
Journal Article
Closed access
PDF file
PGPeter Gallagher
Peter Gallagher
MTMike Tweed
Mike Tweed
SHSean Hanna
Sean Hanna
HWHelen Winter
Helen Winter
KHKath Hoare
Kath Hoare

6 August 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
LGLeonid Gibiansky
Leonid Gibiansky
CPChaitali Passey
Chaitali Passey
JVJenna Voellinger
Jenna Voellinger
RGRudy Gunawan
Rudy Gunawan
WHWilliam D. Hanley
William D. Hanley
HWHelen Winter
Helen Winter
Tisotumab vedotin is an investigational antibody–drug conjugate (ADC) for treatment of solid tumors expressing tissue factor with accelerated approval from the US Food and Drug Administration for treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. This study describes development of a population pharmacokinetic (PK) model to assess the PK profile of tisotumab vedotin and microtubule‐disrupting agent monomethyl auristatin E (MMAE) using data from 399 patients with solid tumors across four phase I/II trials. The ADC–MMAE model describes ADC and MMAE concentrations following intravenous administration of tisotumab vedotin. This four‐compartment model comprises a two‐compartment ADC model with parallel linear and Michaelis–Menten elimination, a delay compartment, and a one‐compartment MMAE model. Nonspecific linear clearance of ADC was 1.42 L/day, central volume of distribution (Vc) was 3.10 L, and median terminal half‐life of ADC was 4.04 days. Apparent clearance of MMAE was 42.8 L/day, and apparent volume of distribution was 2.09 L. Terminal slope of the MMAE concentration–time curve was defined by the delay compartment rate with a half‐life of 2.56 days. Patients with higher body weight and lower albumin concentration had faster ADC clearance. Male patients and those with higher body weight and lower albumin concentration had higher Vc. Body weight was the most influential covariate influencing distribution and elimination of ADC and MMAE, thus supporting weight‐based dosing of tisotumab vedotin. Presence of antidrug antibodies (detected in 3.3% of patients) did not affect key PK parameters or exposures for ADC and MMAE.

28 June 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
OAOlena Anoshchenko
Olena Anoshchenko
MAMazin Abdelghany
Mazin Abdelghany
ALAmos Lichtman
Amos Lichtman
RDRan Duan
Ran Duan
HCHenry Chen
Henry Chen
RHRita Humeniuk
Rita Humeniuk
There is an unmet need for safe and efficacious oral therapies for COVID‐19 with low potential for drug–drug interactions. Obeldesivir is an orally administered nucleoside prodrug that has shown antiviral potency in nonclinical studies against SARS‐CoV‐2 and its circulating variants. Obeldesivir is metabolized to the active nucleoside triphosphate (GS‐443902), which acts as an inhibitor of the SARS‐CoV‐2 RNA‐dependent RNA polymerase, thereby inhibiting viral RNA synthesis. Here, we report the safety, tolerability, and pharmacokinetics from a first‐in‐human, randomized, placebo‐controlled, phase I study following oral administration of obeldesivir and a phase I, open‐label absorption, distribution, metabolism, and excretion study following oral administration of [14C]‐obeldesivir. Overall, obeldesivir was safe and well tolerated at single and multiple doses between 100 and 1,600 mg, with low potential for QT prolongation as assessed by QT‐concentration analysis. The exposures to GS‐441524 increased dose proportionally in the 100–900‐mg dose range. GS‐441524 accumulated by 35% after twice‐daily and 12% after once‐daily dosing for 5 days. Dose‐proportional increases in the intracellular concentration of GS‐443902 were also observed in peripheral blood mononuclar cells. Plasma exposure of GS‐441524 was not significantly altered by food intake. Following oral administration of [14C]‐obeldesivir (500 mg; 100 μCi), the mean cumulative [14C]‐dose recovery was 90.7% with 58.5% in urine and 32.2% in feces. GS‐441524 was the predominant plasma component (90% of 14C‐area under the concentration–time curve) and was primarily eliminated via renal excretion. Collectively, data from these studies support selection of the obeldesivir 350 mg twice‐daily dosing regimen for further evaluation in phase III studies for COVID‐19.

26 October 2004 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HWH Winter
H Winter
CTC Trapnell
C Trapnell
JSJ Slattery
J Slattery
MJM Jacobson
M Jacobson
DGD Greenspan
D Greenspan
JUJashvant D Unadkat
Jashvant D Unadkat

25 September 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
RHRita Humeniuk
Rita Humeniuk
KJKavita Juneja
Kavita Juneja
SCShuguang Chen
Shuguang Chen
SEScott Ellis
Scott Ellis
OAOlena Anoshchenko
Olena Anoshchenko
MDMark Dresser
Mark Dresser
Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration routes, including localized pulmonary delivery, can lower systemic exposure and maximize exposure at the site of action. This study evaluated the pharmacokinetics (PK) and safety of inhaled RDV in healthy adults. This phase Ia, randomized, placebo‐controlled study evaluated inhaled RDV in healthy participants randomized 4:1 to receive RDV or placebo as single doses (4 cohorts) or multiple once‐daily doses (3 cohorts). Doses in cohorts 1–6 were administered as an aerosolized solution for inhalation through a sealed facemask; doses in cohort 7 were administered as an aerosolized solution for inhalation through a mouthpiece. Safety was assessed throughout the study. Seventy‐two participants were enrolled (inhaled RDV, n = 58 and placebo, n = 14). Following single RDV doses, RDV, GS‐704277, and GS‐441524 plasma PK parameters indicated dose‐proportional increases in area under the concentration‐time curve (AUC) extrapolated to infinite time, AUC from time zero to last quantifiable concentration, and maximum observed concentration. Analyte plasma concentrations after multiple RDV doses were consistent with those for single‐dose RDV. Analyte plasma exposures were lower when RDV was administered with a mouthpiece versus a sealed facemask. The most common adverse events included nausea, dizziness, and cough. Single‐ and multiple‐dose inhaled RDV exhibited linear and dose‐proportional plasma PK. Administration of RDV via inhalation was generally safe and well‐tolerated.

31 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CPChi‐Chi Peng
Chi‐Chi Peng
RHRita Humeniuk
Rita Humeniuk
ARAnuja Raut
Anuja Raut
AKAnna Kwan
Anna Kwan
LMLily Mak
Lily Mak
LCLuzelena Caro
Luzelena Caro